Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
rivastigmine
3M Health Care Limited
N06DA03
rivastigmine
Psychoanaleptics, , Anticholinesterases
Alzheimer Disease
Symptomatic treatment of mild to moderately severe Alzheimer's dementia.
Revision: 1
Withdrawn
2014-04-03
39 B. PACKAGE LEAFLET Medicinal product no longer authorised 40 PACKAGE LEAFLET: INFORMATION FOR THE USER RIVASTIGMINE 3M HEALTH CARE LTD. 4.6 MG/24 H TRANSDERMAL PATCH RIVASTIGMINE 3M HEALTH CARE LTD. 9.5 MG/24 H TRANSDERMAL PATCH rivastigmine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Rivastigmine 3M Health Care Ltd. is and what it is used for 2. What you need to know before you use Rivastigmine 3M Health Care Ltd. 3. How to use Rivastigmine 3M Health Care Ltd. 4. Possible side effects 5. How to store Rivastigmine 3M Health Care Ltd. 6. Contents of the pack and other information 1. WHAT RIVASTIGMINE 3M HEALTH CARE LTD. IS AND WHAT IT IS USED FOR The active substance of Rivastigmine 3M Health Care Ltd. is rivastigmine. Rivastigmine belongs to a class of substances called cholinesterase inhibitors. In patients with Alzheimer’s dementia, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Rivastigmine 3M Health Care Ltd. allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease. Rivastigmine 3M Health Care Ltd. is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affec Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Rivastigmine 3M Health Care Ltd. 4.6 mg/24 h transdermal patch 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch releases 4.6 mg of rivastigmine per 24 hours. Each transdermal patch of 4.15 cm 2 contains 7.17 mg of rivastigmine. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Transdermal patch Rectangular patches, approximately 2.5 cm by 1.8 cm with rounded corners. Each patch consists of a combination of a removable, transparent, split release liner, a functional layer containing drug-in- adhesive (DIA) matrix, and a protective backing layer. The backing layer is transparent to translucent, labelled with “R5” in a repeated pattern. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of mild to moderately severe Alzheimer’s dementia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be initiated and supervised by a physician experienced in the diagnosis and treatment of Alzheimer’s dementia. Diagnosis should be made according to current guidelines. Similar to any treatment initiated in patients with dementia, therapy with rivastigmine should only be started if a caregiver is available to regularly administer and monitor the treatment. Posology TRANSDERMAL PATCHES RIVASTIGMINE_ IN VIVO_ RELEASE RATES PER 24 H Rivastigmine 4.6 mg/24 h 4.6 mg Rivastigmine 9.5 mg/24 h 9.5 mg Rivastigmine 13.3 mg/24 h * 13.3 mg * A marketing authorisation for Rivastigmine 3M Health Care Ltd. 13.3 mg/24 h transdermal patch is currently not available, this presentation may although be available from other marketing authorisation holders. Initial dose Treatment is started with 4.6 mg/24 h. Maintenance dose After a minimum of four weeks of treatment and if well tolerated according to the treating physician, the dose of 4.6 mg/24 h should be increased to 9.5 mg/24 h, the daily recommended effective dose, which should be continued for as long a Przeczytaj cały dokument